Haijiao Zhang, M.D.

  • Assistant Professor of Division of Oncological Sciences, School of Medicine
  • OHSU Knight Cancer Institute, School of Medicine

Biography

Haijiao Zhang received her Bachelor and Master of Medicine degree from Jilin University in China and then earning an MD at Hannover Medical School in Germany. She joined Dr. Jeffrey Tyner’s laboratory as a postdoc in 2015 .The focus of her research in the Tyner lab has been oncogenic signaling and drug resistance mechanisms associated with hematologic malignancies. Between 2018 and 2019, Dr. Zhang embarked on a year-long visiting scholar opportunity in Dr. Ravi Majeti’s laboratory at Stanford University. In 2021, Dr. Zhang established her laboratory in the Division of Oncological Science at OHSU to study chromosome and copy number aberrations and WT1 in leukemia.

Education and training

  • Degrees

    • B.Med., 2010, Jilin University
    • M.Med., 2012, Jilin University
    • D.Med., 2015, Hannover Medical School

Memberships and associations:

  • American Society of Hematology (ASH)
  • American Association for Cancer Research (AACR)
  • European Hematology Association (EHA)
  • Knight Cancer Institute Translational Oncology Research

Areas of interest

  • Leukemia
  • Wilm’s tumor gene isoforms and mutations
  • Chromosome and Copy Number Deletion
  • Drug biomarkers and resistance mechanism

Additional information

Publications

Elsevier pure profile

Selected publications

  • Allen B, Bottomly D, Köhnke T, Wang A, Lin HY, Johnson K, Kenna I, Streltsova A, Martin E, Chen R, Savoy L, Long N, Ryabinin P, Kurtz SE, Eide CA, Carlos A, Kaempf A, Liu T, Tognon C, Searles R, Piehowski PD, Gosline SJC, Agarwal A, Chang BH, Barton M, Druker BJ, McWeeney SK, Majeti R, Tyner JW, Zhang H. A CEBPB/IL-1β/TNF-α feedback loop drives drug resistance to venetoclax and MDM2 inhibitors in monocytic leukemia. Blood. 2025 May 22;145(21):2488-2506.
  • Zhang H, Nakauchi Y, Köhnke T, Stafford M, Bottomly D, Thomas R, Wilmot B, McWeeney SK, Majeti R, Tyner JW. Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia. Nat Cancer. 2020 Aug;1(8):826-839. doi: 10.1038/s43018-020-0103-x. Epub 2020 Aug 18. PubMed PMID: 33123685; PubMed Central PMCID: PMC7591155.
  • ect Zhang H, Wilmot B, Bottomly D, Dao KT, Stevens E, Eide CA, Khanna V, Rofelty A, Savage S, Reister Schultz A, Long N, White L, Carlos A, Henson R, Lin C, Searles R, Collins RH, DeAngelo DJ, Deininger MW, Dunn T, Hein T, Luskin MR, Medeiros BC, Oh ST, Pollyea DA, Steensma DP, Stone RM, Druker BJ, McWeeney SK, Maxson JE, Gotlib JR, Tyner JW. Genomic landscape of neutrophilic leukemias of ambiguous diagnosis. Blood. 2019 Sep 12;134(11):867-879. 
  • Zhang H, Savage S, Schultz AR, Bottomly D, White L, Segerdell E, Wilmot B, McWeeney SK, Eide CA, Nechiporuk T, Carlos A, Henson R, Lin C, Searles R, Ho H, Lam YL, Sweat R, Follit C, Jain V, Lind E, Borthakur G, Garcia-Manero G, Ravandi F, Kantarjian HM, Cortes J, Collins R, Buelow DR, Baker SD, Druker BJ, Tyner JW. Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms. Nat Commun. 2019 Jan 16;10(1):244. PubMed PMID: 30651
  • Zhang H, Coblentz C, Watanabe-Smith K, Means S, Means J, Maxson JE, Tyner JW. Gain-of-function mutations in granulocyte colony-stimulating factor receptor (CSF3R) reveal distinct mechanisms of CSF3R activation. J Biol Chem. 2018 May 11;293(19):7387-7396. doi: 10.1074/jbc.RA118.002417. Epub 2018 Mar 23. PubMed PMID: 29572350; PubMed Central PMCID: PMC5950016.
  • Zhang H, Reister Schultz A, Luty S, Rofelty A, Su Y, Means S, Bottomly D, Wilmot B, McWeeney SK, Tyner JW. Characterization of the leukemogenic potential of distal cytoplasmic CSF3R truncation and missense mutations. Leukemia. 2017 Dec;31(12):2752-2760. doi: 10.1038/leu.2017.126. Epub 2017 Apr 25. PubMed PMID: 28439110; PubMed Central PMCID: PMC5682244.
  • Zhang H, Means S, Schultz AR, Watanabe-Smith K, Medeiros BC, Bottomly D, Wilmot B, McWeeney SK, Kükenshöner T, Hantschel O, Tyner JW. Unpaired Extracellular Cysteine Mutations of CSF3R Mediate Gain or Loss of Function. Cancer Res. 2017 Aug 15;77(16):4258-4267. doi: 10.1158/0008-5472.CAN-17-1052. Epub 2017 Jun 26. PubMed PMID: 28652245; PubMed Central PMCID: PMC5763920.
  • Zhang H, Goudeva L, Immenschuh S, Schambach A, Skokowa J, Eiz-Vesper B, Blasczyk R, Figueiredo C. miR-155 is associated with the leukemogenic potential of the class IV granulocyte colony-stimulating factor receptor in CD34⁺ progenitor cells. Mol Med. 2015 Apr 9;20(1):736-46. doi: 10.2119/molmed.2014.00146. PubMed PMID: 25730818; PubMed Central PMCID: PMC4398671.